Daishin Balance No.19 Special Purpose Acquisition Co., Ltd. (KOSDAQ:482690)

Ligand Pharmaceuticals Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024
Period Ending	Mar 31, 2025	Dec 31, 2024
Cash & Equivalents	2,278	2,300
Cash & Short-Term Investments	2,278	2,300
Other Receivables	-	44.47
Receivables	-	44.47
Other Current Assets	0.23	0.23
Total Current Assets	2,278	2,344
Long-Term Investments	11,137	11,000
Total Assets	13,415	13,344
Other Current Liabilities	0.17	13.06
Total Current Liabilities	0.17	13.06
Long-Term Debt	1,739	1,706
Long-Term Deferred Tax Liabilities	158.23	145.67
Other Long-Term Liabilities	-	-0
Total Liabilities	1,897	1,865
Common Stock	561.5	561.5
Additional Paid-In Capital	10,968	10,968
Retained Earnings	-11.69	-50.07
Shareholders' Equity	11,518	11,479
Total Liabilities & Equity	13,415	13,344
Total Debt	1,739	1,706
Net Cash (Debt)	538.98	593.4
Net Cash Per Share	236.52	656.53
Filing Date Shares Outstanding	5.62	5.62
Total Common Shares Outstanding	5.62	5.62
Working Capital	2,278	2,331
Book Value Per Share	2051.24	2044.41
Tangible Book Value	11,518	11,479
Tangible Book Value Per Share	2051.24	2044.41

Source: S&P Global Market Intelligence. Standard template. Financial Sources.